Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2008 / Cilt: 34 - Sayı: 1

Significance of insulin-like growth factor-I expression in bladder tumors

Mesane tümörlerinde insülin benzeri büyüme etkeni-I ekspresyonunnun önemi

Pages
9–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We found no association between tumor grade, stage, and recurrence and insulin-like growth factor-I staining degree in bladder tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Insulin-like growth factor-I is a mitogenic peptide which overexpression involved in the aberrant cell proliferation and malign transformation.
📊
Key Findings & Data:Materials and Methods: 53 patients that performed transurethral tumor resection or radical cystectomy between 2002 and 2007 were included in this study.
💡
Conclusion & Impact:Conclusion: We found no association between tumor grade, stage, and recurrence and insulin-like growth factor-I staining degree in bladder tumors.
🔬Design:Research Article
📍Scope:2002 Verileri
⚙️Variables:Tıbbi kayıtlar · İnsülin-benzeri büyüme faktörü I · Neoplazm evrelendirilmesi

Abstract

Insulin-like growth factor-I is a mitogenic peptide which overexpression involved in the aberrant cell proliferation and malign transformation. It was thought that it can show the malign behavior of bladder tumors. Our aim in this study is to investigate the relationship between insulin like growth factor expression and tumor grade, stage and recurrence in patients with bladder tumor. Materials and Methods: 53 patients that performed transurethral tumor resection or radical cystectomy between 2002 and 2007 were included in this study. Insulin like growth factor-I staining was determined by immunohistochemically from the bladder tumor tissue. Then we investigated the relationship between insulin like growth factor expression in bladder tumor tissue and tumor grade, stage, and recurrence. Results: The mean age was 64.4±11.9, 32 patients have low grade, 21 have high grade; 35 have superficial, 18 have muscle invasive tumor. Of 35 patients with superficial tumors, 25 patients have regular follow-up and the mean follow-up duration was 21.9±8.1 month. There was no significant difference in insulin-like growth factor-I staining degree between low grade and high grade tumors. Insulin-like growth factor-I staining degree was same in both superficial and muscle invasive tumors. We found no relationship between recurrence and insulin-like growth factor-I staining degree. Conclusion: We found no association between tumor grade, stage, and recurrence and insulin-like growth factor-I staining degree in bladder tumors.

Özet

İnsülin benzeri büyüme etkeni-I peptid yapıda bir hormon olup aşırı ekspresyonunun anormal hücre proliferasyonuna ve malin transformasyona neden olmaktadır. Mesane tümörlerinin malinite potansiyelini gösterebileceği düşünülmektedir. Bu çalışmamızdaki amacımız mesane tümörlü hastalarda tümör dokusunda insulin benzeri büyüme faktörü-I ekspresyonu ile tümör derece, evre ve nüks arasındaki ilişkiyi incelemektir. Çalışmaya 2002-2007 yılları arasında mesane tümörü nedeniyle transüretral rezeksiyon veya radikal sistektomi yapılan 53 hasta alındı. İnsülin benzeri büyüme faktörü-I tayini immünohistokimyasal olarak tümör dokusunda bakıldı. Sonrasında insulin benzeri büyüme faktörü-I ekspresyonu ile tümör derece, evre ve nüks ilişkisini araştırdık. Yaş ortalaması 64.4±11.9 olup hastaların 32’sinin düşük derece, 21’inin yüksek derece; 35’inin yüzeyel, 18’inin de kas invaziv tümörü mevcuttu. Yüzeyel tümörlü 35 hastadan 25’inin ortalama 21.9±8.1 ay takibi vardı. Düşük dereceli tümörler ile yüksek dereceli tümörler arasında IGF-I boyanma derecesi açısından anlamlı fark saptanmadı. Ayrıca yüzeyel tümörlerde IGF-I boyanma derecesi invaziv tümörler ile aynı saptandı. İzlenebilen hastalarda ise nüks ile IGF-I boyanması arasında bir ilişki görülmedi. Mesane tümörü dokusunda insulin benzeri büyüme etkeni-I boyanma derecesinin tümör derece, evre ve nüksü ile belirleyici ilişkisi olmadığı sonucuna vardık.

🔖

Cite This Article

ÖZBAKIR, F., KAPLAN, M., USTA, U., AKTOZ, T., ATAKAN, İ. H., İNCİ, O. (2008). Significance of insulin-like growth factor-I expression in bladder tumors. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 34 - Sayı: 1, 9–14. https://ajindex.com/articles/329069

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bedük Y: Mesane tümörleri. Anafarta K, Göğüş O, Be- dük Y, Arıkan N (Editörler). Temel Üroloji. Ankara: Gü- neş Kitabevi; 707-26, 1998
  2. Greenlee RM: Cancer statistics. CA Cancer J Clin.; 50: 7, 2000
  3. Ozen H, Hall MC: Bladder cancer. Curr Opin Oncol.; 12: 255-259, 2000
  4. Shairat SF, Kim JH, Andrews B, et al: Preoperative plasma levels of transforming growth factor beta (1) st- rongly predict clinical outcome in patients with bladder carcinoma. Cancer. 92: 2985-2992, 2001
  5. Andrews B, Shairat SF, Kim JH, et al: Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 167: 1475-1481, 2002
  6. Gohji K, Fujimoto N, Komiyama T, et al: Elevation of serum levels of matrix metalloproteinase-2 and 3 as new predictors of recurrence in patients with urothelial carci- noma. Cancer. 78: 2379-2387, 1996
  7. Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature. 313: 745-747, 1985
  8. Macaulay VM: Insulin-like growth factors and cancer. Brt J Cancer. 65: 311-320, 1992
  9. Wang Y, Hailey J, Williams D, et al: Inhibition of Insu- lin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti- IGF-IR antibody. Mol Cancer Ther. 4: 1214-1221, 2005
  10. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma Insulin-like growth factor-I and prostate cancer risk: A prospective study. Science. 279: 563-566, 1998
  11. Ma J, Pollak M, Giovannucci E, et al: Prospective stu- dy of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding prote- in-3. J Natl Cancer Inst; 91: 620-625, 1999
  12. Vadgama JV, Wu Y, Data G, et al: Plasma Insulin-like growth factor-I and serum IGF-binding protein-3 can be associated with the progression of breast cancer and pre- dict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology. 57: 330-340, 1999
  13. Decensi A, Veronesi U, Miceli R, et al: Relationships between plasma insulin-like growth factor-I and insulin- like growth factor binding protein-3 and second breast cancer risk in a prevention trial of Fenretinide. Clin Can- cer Res. 9: 4722-4729, 2003
  14. Xie QX, Lin XC, Zhang MF, Han CX, Guo YH: Exp- ression of IGF-I and IGF-IR in bladder cancer. Ai Zheng. 23: 707-779, 2004
  15. Sauter G, Algaba F, Amin M, et al: Tumors of the uri- nary system: Non-invasive urothelial neoplasias. In: Eble JN, Saute